

Ref: ADL/SE/2023-24/81
October 19, 2023

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Ref: Compliance of Regulation 33 and Regulation 30 of SEBI (LODR) Regulations, 2015.

Sub: Audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2023.

We wish to inform you that Board of Directors at its Meeting held on **Thursday, October 19, 2023**, approved the Audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2023.

Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015 we enclose the following:-

- i. Statement showing the Financial Results,
- ii. Statement of Assets and Liabilities,
- iii. Cash Flow Statement,
- iv. Auditor’s Report on the Financial Results.

Further, please note that the Company has already made necessary arrangement to publish the same in the Newspapers as required under the SEBI (LODR) Regulations, 2015.

The Meeting of the Board of Directors commenced at 12:00 Noon and concluded at 3:40 PM.

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY
ICSI M. No.: A54527



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

AARTI DRUGS LIMITED							
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEP' 2023							
(Rs. in lakhs except for share data)							
Sr. No.	Particulars	Standalone					
		Quarter Ended			Period Ended		Year Ended
		30th Sep 2023 (Audited)	30th Jun 2023 (Audited)	30th Sep 2022 (Audited)	30th Sep 2023 (Audited)	30th Sep 2022 (Audited)	31st Mar 2023 (Audited)
I	Revenue from operations	57,754	59,163	62,483	116,917	117,603	249,797
II	Other income	74	66	9	139	33	223
III	Total Income (I + II)	57,828	59,228	62,492	117,056	117,637	250,020
IV	Expenses :						
	(a) Cost of materials consumed	39,197	39,902	43,556	79,099	86,559	170,244
	(b) Purchase of stock-in-trade	807	1,125	1,317	1,932	2,583	4,701
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(862)	(728)	(1,516)	(1,590)	(7,506)	(672)
	(d) Employee benefits expense	2,004	2,066	1,793	4,070	3,474	7,499
	(e) Finance costs	755	777	827	1,532	1,506	3,253
	(f) Depreciation and amortisation expense	1,178	1,175	1,192	2,353	2,375	4,729
	(g) Other expenses	10,065	9,607	10,315	19,672	20,002	39,784
	Total expenses (IV)	53,145	53,924	57,484	107,069	108,993	229,539
V	Profit before exceptional items and tax (III - IV)	4,683	5,304	5,008	9,987	8,643	20,481
VI	Exceptional items	-	-	-	-	-	-
VII	Profit before tax (V - VI)	4,683	5,304	5,008	9,987	8,643	20,481
VIII	Tax Expenses :						
	Provision for taxation - Current	1,100	1,275	1,300	2,375	2,200	5,325
	- MAT credit	-	-	-	-	-	-
	- Earlier year	-	-	-	-	-	-
	Provision for deferred taxation	125	75	50	200	150	(125)
	Total tax expenses (VIII)	1,225	1,350	1,350	2,575	2,350	5,200
IX	Profit / (Loss) for the Year (VII - VIII)	3,458	3,954	3,658	7,412	6,293	15,281
X	Other Comprehensive Income						
	Item that will not to be reclassified to statement of Profit and Loss						
	Fair value changes on Investments, net	-	-	-	-	-	(54)
	Remeasurement of defined benefit Liability/Assets,	-	-	-	-	-	(87)
	Total Other Comprehensive Income,net	-	-	-	-	-	(142)
XI	Total Comprehensive Income for the Year (IX+X)	3,458	3,954	3,658	7,412	6,293	15,139
XII	Paid of equity share Capital (face value of Rs.10 each)	9,194	9,260	9,260	9,194	9,260	9,260
	Profit attributable to :						
	Owner of the Company	3,458	3,954	3,658	7,412	6,293	15,281
	Non- Controlling Interest	-	-	-	-	-	-
	Total Comprehensive Income attributable to :						
	Owner of the Company	3,458	3,954	3,658	7,412	6,293	15,139
	Non- Controlling Interest	-	-	-	-	-	-
XIII	Earning per equity share (in Rs.) (not annualised)						
	(1) Basic	3.75	4.27	3.95	8.02	6.80	16.50
	(2) Diluted	3.75	4.27	3.95	8.02	6.80	16.50

Place: Mumbai
Date: 19th October' 2023



For AARTI DRUGS LIMITED

Prakash M. Patil
Prakash M. Patil
(Chairman, Managing Director&CEO)
DIN: 00005618



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

AARTI DRUGS LIMITED							
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEP' 2023							
(Rs. in lakhs except for share data)							
Sr. No.	Particulars	Consolidated					
		Quarter Ended			Period Ended		Year Ended
		30th Sep 2023 (Audited)	30th Jun 2023 (Audited)	30th Sep 2022 (Audited)	30th Sep 2023 (Audited)	30th Sep 2022 (Audited)	31st Mar 2023 (Audited)
I	Revenue from operations	64,154	66,111	68,772	130,264	130,968	271,605
II	Other income	69	60	5	129	32	219
III	Total Income (I + II)	64,222	66,171	68,778	130,393	131,000	271,825
IV	Expenses :						
	(a) Cost of materials consumed	39,566	40,861	44,671	80,427	90,752	176,897
	(b) Purchase of stock-in-trade	4,218	3,942	4,565	8,160	7,460	12,129
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(881)	(168)	(1,122)	(1,049)	(7,204)	(175)
	(d) Employee benefits expense	2,545	2,547	2,205	5,092	4,287	9,202
	(e) Finance costs	825	854	847	1,679	1,529	3,329
	(f) Depreciation and amortisation expense	1,261	1,260	1,266	2,521	2,520	5,032
	(g) Other expenses	11,061	10,522	11,027	21,583	21,533	42,992
	Total expenses (IV)	58,595	59,817	63,458	118,413	120,877	249,407
V	Profit before exceptional items and tax (III - IV)	5,627	6,353	5,319	11,980	10,123	22,418
VI	Exceptional items	-	-	-	-	-	-
VII	Profit before tax (V - VI)	5,627	6,353	5,319	11,980	10,123	22,418
VIII	Tax Expenses :						
	Provision for taxation - Current	1,541	1,479	1,382	3,019	2,590	5,886
	- MAT credit	-	-	-	-	-	-
	- Earlier year	-	-	-	-	-	-
	Provision for deferred taxation	126	78	64	203	181	(103)
	Total tax expenses (VIII)	1,666	1,557	1,446	3,223	2,771	5,782
IX	Profit / (Loss) for the Year (VII - VIII)	3,960	4,797	3,874	8,757	7,351	16,636
X	Other Comprehensive Income						
	Item that will not to be reclassified to statement of Profit and Loss						
	Fair value changes on Investments, net	-	-	-	-	-	(54)
	Remeasurement of defined benefit Liability/Assets, net	-	-	-	-	-	(95)
	Total Other Comprehensive Income, net	-	-	-	-	-	(150)
XI	Total Comprehensive Income for the Year (IX+X)	3,960	4,797	3,874	8,757	7,351	16,486
XII	Paid of equity share Capital (face value of Rs.10 each)	9,194	9,260	9,260	9,194	9,260	9,260
	Profit attributable to :						
	Owner of the Company	3,959	4,785	3,875	8,744	7,354	16,631
	Non- Controlling Interest	1.39	11.73	-1.16	13.12	-2.47	4.84
	Total Comprehensive Income attributable to :						
	Owner of the Company	3,959	4,785	3,875	8,744	7,354	16,481
	Non- Controlling Interest	1.39	11.73	(1.16)	13.12	(2.47)	4.84
XIII	Earning per equity share (in Rs.) (not annualised)						
	(1) Basic	4.29	5.18	4.18	9.47	7.94	17.97
	(2) Diluted	4.29	5.18	4.18	9.47	7.94	17.97

Place: Mumbai
Date: 19th October' 2023



For AARTI DRUGS LIMITED

Prakash M. Patil
Prakash M. Patil
(Chairman, Managing Director&CEO)
DIN: 00005618



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: finacc@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

AARTI DRUGS LIMITED				
STATEMENT OF ASSETS AND LIABILITIES AS AT 30th SEP' 2023				
Particulars	Standalone		(Rs. in lakhs) Consolidated	
	30th Sep 2023	31st Mar 2023	30th Sep 2023	31st Mar 2023
ASSETS				
1 Non - Current Assets				
Property, Plant and Equipment	62,544	63,199	66,637	67,325
Right of use Assets	181	219	181	219
Capital work - in - progress	24,632	16,075	30,473	21,035
Intangible assets	26	31	121	79
Financial Assets				
Investments	2,833	2,862	1,851	1,880
Other Non- Current Assets	1,928	2,211	2,110	2,367
Total Non- Current Assets	92,144	84,596	1,01,373	92,905
2 Current Assets				
Inventories	46,740	47,773	51,523	51,629
Financial Assets				
(i) Trade receivable	65,141	80,168	70,357	86,484
(ii) Cash and cash equivalents	272	268	1,272	896
(iii) Other Current Financial Assets	1,150	1,160	1,227	1,221
Other current assets	5,989	5,585	9,432	9,005
Total Current Assets	1,19,292	1,34,953	1,33,810	1,49,235
TOTAL ASSETS	2,11,436	2,19,550	2,35,183	2,42,140
EQUITY AND LIABILITIES				
1 EQUITY				
Share Capital	9,194	9,260	9,194	9,260
Other Equity	1,02,332	1,02,170	1,11,751	1,09,983
Total Equity Attributable to Equity Holders of the Company	1,11,525	1,11,430	1,20,944	1,19,243
Non- Controlling Interests	-	-	36.45	23.33
Total Equity	1,11,525	1,11,430	1,20,980	1,19,267
LIABILITIES				
2 Non-current liabilities				
Financial Liabilities				
(i) Borrowings	17,188	16,189	21,210	20,468
(ii) Lease Liability	52	40	52	40
(iii) Other financial liability	1,529	1,244	1,529	1,244
Provisions	559	711	832	727
Deferred tax liabilities (Net)	7,037	6,837	7,300	7,097
Total of Non current liabilities	26,365	25,020	30,923	29,575
3 Current liabilities				
Financial Liabilities				
(i) Borrowings	32,627	37,120	37,507	40,184
(ii) Lease Liability	141	199	141	199
(iii) Trade payables				
Dues of micro enterprises and small enterprises	1,581	1,362	2,339	2,078
Dues of creditors other micro enterprises and small enterprises	35,292	40,540	38,526	45,948
Provisions	116	263	487	437
Other current liabilities	3,788	3,616	4,279	4,451
Total of current liabilities	73,545	83,099	83,280	93,298
TOTAL EQUITY AND LIABILITIES	2,11,436	2,19,550	2,35,183	2,42,140

The above results for the quarter and Period ended 30th September, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 19th October, 2023.

The company has completed buyback of 6,65,000 equity shares of face value Rs.10/- representing up to 0.72% of the total number of Equity Shares of the Company at a price of Rs. 900/- per Equity Share (including premium of Rs. 890/- per Equity Share) payable in cash for an aggregate amount of up to Rs. 59,85,00,000/- (excluding transaction costs such as brokerage, Buyback tax, securities transaction tax, goods and service tax, stamp duty etc.) ("Buyback Size") on 24th August, 2023. Post buyback Paid up Share Capital of the Company reduced to Rs. 91,93,50,000 divided into 9,19,35,000 Equity Shares of Rs.10/- each.

Earnings per share for each of the three months ended 30th September 2023 and 30th June 2023 will not add up to earnings per share for the six months ended 30th September 2023, on account of buyback of equity shares.

Company has only one business segment i.e. pharmaceuticals.

Figures for the previous Quarter have been regrouped or rearranged wherever necessary.

The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors.

Place: Mumbai
Date: 19th October' 2023



For AARTI DRUGS LIMITED

Prakash M. Patil
(Chairman, Managing Director & CEO)
DIN : 00005618



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

AARTI DRUGS LIMITED					
CASH FLOW STATEMENT AS AT 30TH SEP' 2023 (Rs. in lakhs)					
S.No	Particulars	Standalone		Consolidated	
		30th Sep 2023	30th Sep 2022	30th Sep 2023	30th Sep 2022
A.	Cash Flow from Operating Activities				
	Net Profit before Tax and Exceptional Items	9,987	8,643	11,980	10,123
	ADJUSTMENT FOR:				
	Depreciation & Amortisation	2,353	2,375	2,521	2,520
	Provision for Doubtful debts /Bad debts	122	-	167	75
	Unrealised Foreign Exchange (Gain)/Loss (Net)	0	143	(224)	118
	Interest Paid	1,532	1,506	1,679	1,529
	Interest Received	(1)	(1)	(3)	(2)
	Dividend Received	(0)	(0)	(0)	(0)
	Investment W/off	29	-	29	-
	Profit on Sale of Assets	-	-	18	-
	Operating Profit before Working Capital Changes	14,023	12,666	16,168	14,364
	Trade & Other Receivable	14,518	4,126	18,008	6,800
	Changes in Inventories	1,033	(6,172)	835	(5,504)
	Trade & Other Payable	(5,226)	(1,911)	(10,214)	(8,880)
	Cash generated from operation	24,347	8,708	24,797	6,780
	Direct Taxes Paid	(2,526)	(2,920)	(2,911)	(3,179)
	Net Cash Flow from Operating Activities	21,821	5,789	21,886	3,601
B.	Cash Flow from Investing Activities				
	Purchase of Fixed Assets / Capital Work in Progress/ Advances	(9,855)	(5,641)	(10,980)	(7,882)
	Sale of PPE	-	-	19	-
	Investments	0	(127)	127	-
	Interest Received	1	1	3	2
	Dividend Received	0.00	0.11	0.00	0.11
	Net Cash Flow from Investing Activities	(9,854)	(5,767)	(10,832)	(7,880)
C.	Cash Flow from Financing Activities				
	Proceeds from Long Term Borrowings	1,211	(1,568)	1,493	456
	Proceeds from Unsecured Loans & from Scheduled Bank	(4,550)	3,262	(3,274)	4,574
	Capital Proceeds	-	-	(127)	-
	Buy Back of shares	(5,985)	-	(5,985)	-
	Buyback Tax	(1,332)	-	(1,332)	-
	Dividend Paid	(7)	-	(7)	-
	Interest Paid	(1,294)	(1,506)	(1,440)	(1,529)
	Net Cash Flow from Financing Activities	(11,957)	189	(10,673)	3,500
	Net Increase in Cash and Cash Equivalents (A+B+C)	11	211	382	(779)
	Opening Cash and Cash Equivalents	210	149	838	2,161
	Closing Cash and Cash Equivalents	221	360	1,220	1,383

Place: Mumbai
Date: 19th October' 2023



For AARTI DRUGS LIMITED

Prakash M. Patil
Prakash M. Patil
(Chairman, Managing Director&CEO)
DIN: 00005618



Independent Auditors' Report on Audit of Standalone Financial Results

To Board of Directors of
Aarti Drugs Limited

Report on the Audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone financial results of Aarti Drugs Limited ("the Company") for the quarter ended 30 September 2023 and the year-to-date results for the period from 1 April 2023 to 30 September 2023, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

1. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
2. give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS-34") prescribed under section 133 of the Companies Act 2013 read with relevant rules thereunder and other accounting principles generally accepted in India of the net profit and total other comprehensive income, and other financial information of the Company for quarter ended 30 September 2023 and year to date results for the period 1 April 2023 to 30 September 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



**Management's Responsibilities for the Standalone Financial Results**

These quarterly financial results as well as the year-to-date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management and the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.





As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management and the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the interim standalone financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the interim condensed standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the interim condensed standalone financial statements

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.





Other Matters

Comparative Audited Standalone Financial Results

- a) The comparative audited standalone financial results for the quarter ended 30 June 2023 were audited by erstwhile statutory auditors, Kirtane & Pandit, LLP (FRN: 105215W/W100057), Chartered Accountants, whose audit report dated 21 July 2023 had expressed an unmodified opinion on financial statements.
- b) The comparative audited standalone financial results for quarter and half year ended 30 September 2022 were audited by erstwhile statutory auditors, Kirtane & Pandit, LLP (FRN: 105215W/W100057), Chartered Accountants whose audit report dated 20 October 2022 had expressed an unmodified opinion on financial statements.
- c) The comparative audited standalone annual financial results for the year ended 31 March 2023 were audited by erstwhile statutory auditors, Kirtane & Pandit, LLP (FRN: 105215W/W100057), Chartered Accountants whose annual auditors report dated 29 April 2023 had expressed an unmodified opinion on financial statements.

Our opinion is not modified in respect of above matters.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W

Tejas Parikh
Partner
Membership No. 123215
UDIN: -23123215BGQLIH4821
Place: Mumbai
Date: 19 October 2023





Independent Auditors' Report on Audit of Consolidated Financial Results

To Board of Directors of Aarti Drugs Limited

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of Aarti Drugs Limited ("Holding company") and its subsidiaries (holding company and its subsidiaries together referred to as "the Group") for the quarter ended 30 September 2023 and for the period from 1 April 2023 to 30 September 2023 ("the Statement"), being submitted by the Holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/ financial information of subsidiaries (refer other matter paras), the Statement:

1. includes the results of the following entities:
 - i. Pinnacle Life Science Private Limited
 - ii. Aarti Speciality Chemicals Limited
 - iii. Pinnacle Chile SpA.
2. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
3. give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS-34") prescribed under section 133 of the Companies Act 2013 read with relevant rules thereunder and other accounting principles generally accepted in India of the consolidated net profit and consolidated total other comprehensive income and other financial information of the Group for quarter ended 30 September 2023 and year to date results for the period 1 April 2023 to 30 September 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit





of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Consolidated Financial Results.

These quarterly financial results as well as the year-to-date consolidated financial results have been prepared on the basis of the interim financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.





As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the interim consolidated financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the interim consolidated financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the interim consolidated financial results.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and





significant audit findings, including any significant deficiencies in internal control that we identify during our audit

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

I. Comparative Audited Consolidated Financial Results

- a) The comparative audited consolidated financial results for the quarter ended 30 June 2023 were audited by erstwhile statutory auditors, Kirtane & Pandit, LLP (FRN: 105215W/W100057), Chartered Accountants, whose audit report dated 21 July 2023 had expressed an unmodified opinion on financial statements.
- b) The comparative audited consolidated financial results for quarter and half year ended 30 September 2022 were audited by erstwhile statutory auditors, Kirtane & Pandit, LLP (FRN: 105215W/W100057), Chartered Accountants whose audit report dated 20 October 2022 had expressed an unmodified opinion on financial statements.
- c) The comparative audited consolidated annual financial results for the year ended 31 March 2023 were audited by erstwhile statutory auditors, Kirtane & Pandit, LLP (FRN: 105215W/W100057), Chartered Accountants whose annual auditors report dated 29 April 2023 had expressed an unmodified opinion on financial statements.

Our opinion is not modified in respect of above matter.

II. Financial Results of Subsidiaries not audited by us.

- a) The consolidated financial results include the unaudited financial results of 1 foreign subsidiary whose interim financial Results/ financial information reflects total assets of Rs. 4,675.13 Lakhs as at 30 September 2023, and total revenues of Rs. 1,626.36 lakhs and Rs.3,452.08 lakhs and total net profit after tax of Rs.112.84 lakhs and Rs. 347.44 lakhs for the quarter ended 30 September 2023 and for the period 1 April 2023 to 30 September 2023 respectively, and cash outflows (net) of Rs. 20.08 lakhs for the period from 1 April 2023 to 30 September 2023 as considered in the consolidated financial results. These unaudited financial statements have been furnished to us by the board of directors and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on such unaudited interim financial





statement. In our opinion and according to the information and explanations given to us by the Board of Directors, these interim financial statements is not material to the Group.

Our opinion is not modified in respect of above matter.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W

Tejas Parikh
Partner
Membership No. 123215
UDIN: -23123215BGQLII3799
Date: 19 October 2023
Place : Mumbai

